Table of Contents

company-logo

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Calithera Biosciences Dividend Announcement

• Calithera Biosciences does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Calithera Biosciences dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Calithera Biosciences Dividend History

Calithera Biosciences Dividend Yield

Calithera Biosciences current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Calithera Biosciences stock? Use our calculator to estimate your expected dividend yield:

Calithera Biosciences Financial Ratios

P/E ratio-0.00
PEG ratio0.00
P/B ratio0.00
ROE8.01%
Payout ratio0.00%
Current ratio3.60
Quick ratio3.60
Cash Ratio3.44

Calithera Biosciences Dividend FAQ

Does Calithera Biosciences stock pay dividends?
Calithera Biosciences does not currently pay dividends to its shareholders.
Has Calithera Biosciences ever paid a dividend?
No, Calithera Biosciences has no a history of paying dividends to its shareholders. Calithera Biosciences is not known for its dividend payments.
Why doesn't Calithera Biosciences pay dividends?
There are several potential reasons why Calithera Biosciences would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Calithera Biosciences ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Calithera Biosciences has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Calithera Biosciences a dividend aristocrat?
Calithera Biosciences is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Calithera Biosciences a dividend king?
Calithera Biosciences is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Calithera Biosciences a dividend stock?
No, Calithera Biosciences is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Calithera Biosciences stocks?
To buy Calithera Biosciences you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Calithera Biosciences stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.